Hantz Financial Services Inc. Sells 22,352 Shares of Pfizer Inc. $PFE

Hantz Financial Services Inc. lowered its position in Pfizer Inc. (NYSE:PFE) by 4.3% during the 2nd quarter, Holdings Channel reports. The firm owned 494,748 shares of the biopharmaceutical company’s stock after selling 22,352 shares during the quarter. Hantz Financial Services Inc.’s holdings in Pfizer were worth $11,993,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. GKV Capital Management Co. Inc. bought a new stake in shares of Pfizer in the first quarter valued at about $27,000. Curio Wealth LLC lifted its holdings in shares of Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,098 shares during the period. Bayforest Capital Ltd acquired a new stake in shares of Pfizer in the first quarter worth $28,000. North Capital Inc. acquired a new stake in Pfizer during the first quarter worth about $28,000. Finally, Harbor Asset Planning Inc. purchased a new stake in Pfizer during the second quarter worth $29,000. 68.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Morgan Stanley cut their target price on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. UBS Group reaffirmed a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a research report on Wednesday, October 1st. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Finally, Citigroup raised their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average price target of $28.13.

Pfizer Price Performance

PFE stock opened at $24.32 on Thursday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a market cap of $138.26 billion, a price-to-earnings ratio of 12.94, a PEG ratio of 0.81 and a beta of 0.55. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $28.64. The firm has a 50 day moving average of $24.82 and a 200-day moving average of $24.25.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the prior year, the firm earned $0.60 earnings per share. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.1%. Pfizer’s payout ratio is presently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.